Targeting orthotopic gliomas with renal-clearable luminescent gold nanoparticles
),
Jie Zheng1(
)
Download citation
546
Views
36
Downloads
65
Crossref
N/A
WoS
55
Scopus
1
CSCD
A major clinical translational challenge in nanomedicine is the potential of toxicity associated with the uptake and long-term retention of non-degradable nanoparticles (NPs) in major organs. The development of inorganic NPs that undergo renal clearance could potentially resolve this significant biosafety concern. However, it remains unclear whether inorganic NPs that can be excreted by the kidneys remain capable of targeting tumors with poor permeability. Glioblastoma multiforme, the most malignant orthotopic brain tumor, presents a unique challenge for NP delivery because of the blood-brain barrier and robust blood-tumor barrier of reactive microglia and macroglia in the tumor microenvironment. Herein, we used an orthotopic murine glioma model to investigate the passive targeting of glutathione-coated gold nanoparticles (AuNPs) of 3 nm in diameter that undergo renal clearance and 18-nm AuNPs that fail to undergo renal clearance. Remarkably, we report that 3-nm AuNPs were able to target intracranial tumor tissues with higher efficiency (2.3× relative to surrounding non-tumor normal brain tissues) and greater specificity (3.0×) than did the larger AuNPs. Pharmacokinetics studies suggested that the higher glioma targeting ability of the 3-nm AuNPs may be attributed to the longer retention time in circulation. The total accumulation of the 3-nm AuNPs in major organs was significantly less (8.4×) than that of the 18-nm AuNPs. Microscopic imaging of blood vessels and renal-clearable AuNPs showed extravasation of NPs from the leaky blood-tumor barrier into the tumor interstitium. Taken together, our results suggest that the 3-nm AuNPs, characterized by enhanced permeability and retention, are able to target brain tumors and undergo renal clearance.
menu
Targeting orthotopic gliomas with renal-clearable luminescent gold nanoparticles
), Jie Zheng1(
)
Abstract
A major clinical translational challenge in nanomedicine is the potential of toxicity associated with the uptake and long-term retention of non-degradable nanoparticles (NPs) in major organs. The development of inorganic NPs that undergo renal clearance could potentially resolve this significant biosafety concern. However, it remains unclear whether inorganic NPs that can be excreted by the kidneys remain capable of targeting tumors with poor permeability. Glioblastoma multiforme, the most malignant orthotopic brain tumor, presents a unique challenge for NP delivery because of the blood-brain barrier and robust blood-tumor barrier of reactive microglia and macroglia in the tumor microenvironment. Herein, we used an orthotopic murine glioma model to investigate the passive targeting of glutathione-coated gold nanoparticles (AuNPs) of 3 nm in diameter that undergo renal clearance and 18-nm AuNPs that fail to undergo renal clearance. Remarkably, we report that 3-nm AuNPs were able to target intracranial tumor tissues with higher efficiency (2.3× relative to surrounding non-tumor normal brain tissues) and greater specificity (3.0×) than did the larger AuNPs. Pharmacokinetics studies suggested that the higher glioma targeting ability of the 3-nm AuNPs may be attributed to the longer retention time in circulation. The total accumulation of the 3-nm AuNPs in major organs was significantly less (8.4×) than that of the 18-nm AuNPs. Microscopic imaging of blood vessels and renal-clearable AuNPs showed extravasation of NPs from the leaky blood-tumor barrier into the tumor interstitium. Taken together, our results suggest that the 3-nm AuNPs, characterized by enhanced permeability and retention, are able to target brain tumors and undergo renal clearance.
References(46)
Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387–6392.
Prabhakar, U.; Maeda, H.; Jain, R. K.; Sevick-Muraca, E. M.; Zamboni, W.; Farokhzad, O. C.; Barry, S. T.; Gabizon, A.; Grodzinski, P.; Blakey, D. C. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013, 73, 2412–2417.
Allen, T. M.; Cullis, P. R. Drug delivery systems: Entering the mainstream. Science 2004, 303, 1818–1822.
Jain, R. K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7, 653–664.
Goldmann, E. The growth of malignant disease in man and the lower animals: With special reference to the vascular system. Lancet 1907, 170, 1236–1240.
Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285, 1182–1186.
Dvorak, H. F.; Brown, L. F.; Detmar, M.; Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 1995, 146, 1029–1039.
Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249–257.
Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11, 812–818.
Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.; Torchilin, V. P.; Jain, R. K. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 1998, 95, 4607–4612.
Groothuis, D. R. The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro Oncol. 2000, 2, 45–59.
Pardridge, W. M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRX 2005, 2, 3–14.
Béduneau, A.; Saulnier, P.; Benoit, J. -P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28, 4947–4967.
Yan, H.; Wang, L.; Wang, J.; Weng, X.; Lei, H.; Wang, X.; Jiang, L.; Zhu, J.; Lu, W.; Wei, X. et al. Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano 2012, 6, 410–420.
Cole, A. J.; David, A. E.; Wang, J. X.; Galbán, C. J.; Yang, V. C. Magnetic brain tumor targeting and biodistribution of long-circulating peg-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials 2011, 32, 6291–6301.
Wilhelm, S.; Tavares, A. J.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H. F.; Chan, W. C. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 2016, 1, 16014.
Chauhan, R. P.; Mathur, R.; Singh, G.; Bag, N.; Singh, S.; Chuttani, K.; Kumar, B. S. H.; Agrawal, S. K.; Mishra, A. K. Evaluation of biotinylated magnetic nanoparticles for tumour imaging. J. Mater. Sci. 2013, 48, 3913–3925.
Yang, X. Q.; Hong, H.; Grailer, J. J.; Rowland, I. J.; Javadi, A.; Hurley, S. A.; Xiao, Y. L.; Yang, Y.; Zhang, Y.; Nickles, R. J. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 2011, 32, 4151–4160.
Meyers, J. D.; Cheng, Y.; Broome, A. M.; Agnes, R. S.; Schluchter, M. D.; Margevicius, S.; Wang, X. N.; Kenney, M. E.; Burda, C.; Basilion, J. P. Peptide-targeted gold nanoparticles for photodynamic therapy of brain cancer. Part. Part. Syst. Charact. 2015, 32, 448–457.
Hu, H.; Huang, P.; Weiss, O. J.; Yan, X. F.; Yue, X. Y.; Zhang, M. G.; Tang, Y. X.; Nie, L. M.; Ma, Y.; Niu, G. PET and NIR optical imaging using self-illuminating 64Cu- doped chelator-free gold nanoclusters. Biomaterials 2014, 35, 9868–9876.
Goel, S.; Chen, F.; Hong, H.; Valdovinos, H. F.; Hernandez, R.; Shi, S. X.; Barnhart, T. E.; Cai, W. B. VEGF121-conjugated mesoporous silica nanoparticle: A tumor targeted drug delivery system. ACS Appl. Mater. Interfaces 2014, 6, 21677–21685.
Chakravarty, R.; Goel, S.; Hong, H.; Chen, F.; Valdovinos, H. F.; Hernandez, R.; Barnhart, T. E.; Cai, W. B. Hollow mesoporous silica nanoparticles for tumor vasculature targeting and pet image-guided drug delivery. Nanomedicine 2015, 10, 1233–1246.
Chen, K.; Li, Z. -B.; Wang, H.; Cai, W. B.; Chen, X. Y. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 2235–2244.
Cai, W. B.; Chen, K.; Li, Z. -B.; Gambhir, S. S.; Chen, X. Y. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J. Nucl. Med. 2007, 48, 1862–1870.
Hong, G. S.; Robinson, J. T.; Zhang, Y. J.; Diao, S.; Antaris, A. L.; Wang, Q. B.; Dai, H. J. In vivo fluorescence imaging with Ag2S quantum dots in the second near-infrared region. Angew. Chem. 2012, 124, 9956–9959.
Perrault, S. D.; Walkey, C.; Jennings, T.; Fischer, H. C.; Chan, W. C. W. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009, 9, 1909–1915.
Gao, J.; Chen, K.; Luong, R.; Bouley, D. M.; Mao, H.; Qiao, T.; Gambhir, S. S.; Cheng, Z. A novel clinically translatable fluorescent nanoparticle for targeted molecular imaging of tumors in living subjects. Nano Lett. 2011, 12, 281–286.
Wang, Y. C.; Liu, Y. J.; Luehmann, H.; Xia, X. H.; Wan, D. H.; Cutler, C.; Xia, Y. N. Radioluminescent gold nanocages with controlled radioactivity for real-time in vivo imaging. Nano Lett. 2013, 13, 581–585.
Son, Y. J.; Jang, J. -S.; Cho, Y. W.; Chung, H.; Park, R. -W.; Kwon, I. C.; Kim, I. -S.; Park, J. Y.; Seo, S. B.; Park, C. R. et al. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J. Control. Release 2003, 91, 135–145.
Noguchi, Y.; Wu, J.; Duncan, R.; Strohalm, J.; Ulbrich, K.; Akaike, T.; Maeda, H. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 1998, 89, 307–314.
Yu, M. X.; Zheng, J. Clearance pathways and tumor targeting of imaging nanoparticles. ACS Nano 2015, 9, 6655–6674.
Storm, G.; Belliot, S. O.; Daemen, T.; Lasic, D. D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Del. Rev. 1995, 17, 31–48.
Gibaud, S.; Demoy, M.; Andreux, J. P.; Weingarten, C.; Gouritin, B.; Couvreur, P. Cells involved in the capture of nanoparticles in hematopoietic organs. J. Pharm. Sci. 1996, 85, 944–950.
Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Del. Rev. 2002, 54, 631–651.
De Jong, W. H.; Borm, P. J. A. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomedicine 2008, 3, 133–149.
Liu, J. B.; Yu, M. X.; Zhou, C.; Yang, S. Y.; Ning, X. H.; Zheng, J. Passive tumor targeting of renal-clearable luminescent gold nanoparticles: Long tumor retention and fast normal tissue clearance. J. Am. Chem. Soc. 2013, 135, 4978–4981.
Liu, J. B.; Yu, M. X.; Ning, X. H.; Zhou, C.; Yang, S. Y.; Zheng, J. PEGylation and zwitterionization: Pros and cons in the renal clearance and tumor targeting of near-IR-emitting gold nanoparticles. Angew. Chem., Int. Ed. 2013, 52, 12572–12576.
Black, K. L.; Ningaraj, N. S. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control 2004, 11, 165–173.
Zheng, J.; Ding, Y.; Tian, B. Z.; Wang, Z. L.; Zhuang, X. W. Luminescent and raman active silver nanoparticles with polycrystalline structure. J. Am. Chem. Soc. 2008, 130, 10472–10473.
Mashimo, T.; Pichumani, K.; Vemireddy, V.; Hatanpaa, K. J.; Singh, D. K.; Sirasanagandla, S.; Nannepaga, S.; Piccirillo, S. G.; Kovacs, Z.; Foong, C. et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 2014, 159, 1603–1614.
Zhou, C.; Long, M.; Qin, Y. P.; Sun, X. K.; Zheng, J. Luminescent gold nanoparticles with efficient renal clearance. Angew. Chem., Int. Ed. 2011, 50, 3168–3172.
Tang, S. H.; Peng, C. Q.; Xu, J.; Du, B. J.; Wang, Q. X.; Vinluan, R. D., III; Yu, M. X.; Kim, M. J.; Zheng, J. Tailoring renal clearance and tumor targeting of ultrasmall metal nanoparticles with particle density. Angew. Chem., Int. Ed. 2016, 55, 16039–16043.
Zhou, C.; Hao, G. Y.; Thomas, P.; Liu, J. B.; Yu, M. X.; Sun, S. S.; Öz, O. K.; Sun, X. K.; Zheng, J. Near-infrared emitting radioactive gold nanoparticles with molecular pharmacokinetics. Angew. Chem. 2012, 124, 10265–10269.
Zhu, Y.; Parada, L. F. The molecular and genetic basis of neurological tumours. Nat. Rev. Cancer 2002, 2, 616–626.
Van Tellingen, O.; Yetkin-Arik, B.; de Gooijer, M. C.; Wesseling, P.; Wurdinger, T.; de Vries, H. E. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist. Updat. 2015, 19, 1–12.
Leten, C.; Struys, T.; Dresselaers, T.; Himmelreich, U. In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models. J. Neurooncol. 2014, 119, 297–306.
Publication history
Copyright
Acknowledgements
This study was partially supported by CPRIT (Nos. RP140544 and RP160866), NIH (No. 1R01DK103363) and a start-up fund from the University of Texas at Dallas to J. Z., UTSW CRI start-up funds, UTSW High Impact/High Risk Grant and NINDS K99/R00 (No. R00NS073735) to W. P. G.
FEEDBACK 
TOP